Quarterly report · Q1
7733.TEDINET S100OX7K
Period2022-04-01 → 2022-06-30
Filed2022-08-09
StandardIFRS
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥214.1bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥868.9bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥191.5bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥40.8bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥27.6bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥38.2bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥149.9bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥27.0bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥18.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥24.9bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥18.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.43T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.36T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.14T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥851.3bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥846.6bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥582.2bn | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥401.4bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥395.5bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥581.1bn | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥510.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥400.4bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥286.4bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥302.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥168.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | −¥26.9bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥23.7bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | ¥5.2bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥33.5bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥21.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥19.53 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥14.54 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥19.52 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥14.53 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 40.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 35.0% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 12
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥24.8bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥298m |
| jpcrp040300-q1r_E02272-000Scientific Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥13.4bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥10.4bn |
| jpcrp040300-q1r_E02272-000Endoscopic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥22.7bn |
| jpcrp040300-q1r_E02272-000Otherreportable segment | segment profit | 2021-04-01 → 2021-06-30 | −¥565m |
| jpcrp040300-q1r_E02272-000Scientific Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02272-000Therapeutic Solutionsreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥14.1bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥38.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 615
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -4059000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | Prior1YTDDuration | -15002000000 | JPY |
| Repayments of long term borrowings fin cf IFRS | CurrentYTDDuration | － | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -15428000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -17822000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | Prior1YTDDuration | -188000000 | JPY |
| Dividends paid to non controlling interests fin cf IFRS | CurrentYTDDuration | -226000000 | JPY |
| Other fin cf IFRS | Prior1YTDDuration | 1057000000 | JPY |
| Other fin cf IFRS | CurrentYTDDuration | 446000000 | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -38955000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -21748000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 14000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 27250000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | -48763000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -16160000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior2YearInstant | 217478000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1YearInstant | 302572000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | Prior1QuarterInstant | 168715000000 | JPY |
| Cash and cash equivalents if different from bs balance IFRS | CurrentQuarterInstant | 286412000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 100014000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 63646000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 24829000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3028000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 191517000000 | JPY |
| Sales to external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Sales to external customers IFRS | Prior1YTDDuration | 191517000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | － | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 6000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 109000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 115000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -115000000 | JPY |
| Intersegment sales IFRS | Prior1YTDDuration | － | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 100014000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 63646000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 24835000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | 3137000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReportableSegmentsMember | 191632000000 | JPY |
| Net sales IFRS | Prior1YTDDuration_ReconcilingItemsMember | -115000000 | JPY |
| Net sales IFRS | Prior1YTDDuration | 191517000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000EndoscopicSolutionsReportableSegmentMember | 22654000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000TherapeuticSolutionsReportableSegmentMember | 14072000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000ScientificSolutionsReportableSegmentMember | 1873000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q1r_E02272-000OtherReportableSegmentMember | -565000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 38034000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -10422000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 27612000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 423000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 1083000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 26952000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 10 of 10 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |